BMS-986278 (Synonyms: Admilparant)

Name: BMS-986278
Brand: MedChemExpress
SKU: HY-139853
Rating: 4.5 (1 reviews)

Cat. No.: HY-139853 Purity: 99.93%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with K_bs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases.

For research use only. We do not sell to patients.

CAS No. : 2170126-74-4

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE BMS-986278

•Pediatr Res. 2025 Jun;97(7):2462-2474. [Abstract]

Histological Imaging/Staining

Bio/Physico-chemical Assay

: BMS-986278 purchased from MedChemExpress. Usage Cited in: Pediatr Res. 2025 Jun;97(7):2462-2474. [Abstract]; BMS-986278 (10 mg/kg; ip; on alternate days, for a total of 14 days) protectd neonates from HYX-induced lung injury C57BL/6 neonatal mouse on PN 3.

: BMS-986278 purchased from MedChemExpress. Usage Cited in: Pediatr Res. 2025 Jun;97(7):2462-2474. [Abstract]; BMS-986278 (10 mg/kg; ip; on alternate days, for a total of 14 days) ameliorated HYX-induced expression of LOX in mouse lung tissue.

: BMS-986278 purchased from MedChemExpress. Usage Cited in: Pediatr Res. 2025 Jun;97(7):2462-2474. [Abstract]; BMS-986278 (10 mg/kg; ip; on alternate days, for a total of 14 days) mitigated HYX-induced LOX activity in the BALF of neonatal mouse pups.

: BMS-986278 purchased from MedChemExpress. Usage Cited in: Pediatr Res. 2025 Jun;97(7):2462-2474. [Abstract]; BMS-986278 (10 μM; 1+6 h; 1 hour prior to 6-hour exposure to Hyperoxia (HYX)) attenuated HYX-induced expression of COLI and LOX in HLF cells.

: BMS-986278 purchased from MedChemExpress. Usage Cited in: Pediatr Res. 2025 Jun;97(7):2462-2474. [Abstract]; BMS-986278 (10 μM; 1+6 h; 1 hour prior to 6-hour exposure to Hyperoxia (HYX)) attenuated HYX-induced p-AKT expression in HLF cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All LPL Receptor Isoform Specific Products:

View All Isoforms

LPAR1 LPAR2 LPAR3 LPAR5 S1PR1 S1PR2 S1PR3 S1PR4 S1PR5

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Kb: 6.9 nM (human LPA1), 4.0 nM (mouse LPA1)^[1]

In Vitro

BMS-986278 is a high-affinity LPA1 antagonist, with K_bs of 6.9 nM and 4.0 nM for human and mouse LPA1 in CHO cells overexpressing LPA1^[1].
BMS-986278 antagonizes Lysophosphatidic acid (LPA)-stimulated calcium flux in normal human lung fibroblasts, with a K_b of 5.8 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BMS-986278 (0.1-10 mg/kg; a single p.o.) completely inhibits LPA-stimulated systemic histamine release in a concentration-dependent manner in CD1 mice^[1].
BMS-986278 (3-30 mg/kg; p.o. twice daily for 14 d) decreases Bleomycin-induced collagen deposition/lung fibrosis in rats^[1].

Pharmacokinetics of BMS-986278 in preclinical species^[1]

	plasma clearance ((mL/min)/kg)	V_ss (L/kg)	oral bioavailability (%)	T_1/2 (h)	plasma protein binding (% free)
mouse	37	5.5	70	2.5	31.4
rat	15	3.5	100	4.5	12.6
monkey	2.0	1.6	79	11	0.8

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (10 weeks) were administered Bleomycin^[1]
Dosage:	3, 10, and 30 mg/kg
Administration:	P.o. twice daily for 14 days
Result:	Resulted in significant decreases in the lung section percent fibrotic area for the 3 mg/kg (48%) and 10 mg/kg (56%) dose groups.

Clinical Trial

Molecular Weight

445.51

Formula

C₂₂H₃₁N₅O₅

CAS No.

2170126-74-4

Appearance

Solid

Color

White to light yellow

SMILES

CCCN(C)C(OCC1=C(N=NN1C)C(C=C2)=NC(C)=C2O[C@H]3CCC[C@H](C(O)=O)C3)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (224.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2446 mL	11.2231 mL	22.4462 mL
5 mM	0.4489 mL	2.2446 mL	4.4892 mL
10 mM	0.2245 mL	1.1223 mL	2.2446 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.95%

Select Batch:

Data Sheet (291 KB) SDS (252 KB)

COA (255 KB) HNMR (259 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Cheng PTW, et, al. Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. J Med Chem. 2021 Nov 11;64(21):15549-15581. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2446 mL	11.2231 mL	22.4462 mL	56.1155 mL
	5 mM	0.4489 mL	2.2446 mL	4.4892 mL	11.2231 mL
	10 mM	0.2245 mL	1.1223 mL	2.2446 mL	5.6115 mL
	15 mM	0.1496 mL	0.7482 mL	1.4964 mL	3.7410 mL
	20 mM	0.1122 mL	0.5612 mL	1.1223 mL	2.8058 mL
	25 mM	0.0898 mL	0.4489 mL	0.8978 mL	2.2446 mL
	30 mM	0.0748 mL	0.3741 mL	0.7482 mL	1.8705 mL
	40 mM	0.0561 mL	0.2806 mL	0.5612 mL	1.4029 mL
	50 mM	0.0449 mL	0.2245 mL	0.4489 mL	1.1223 mL
	60 mM	0.0374 mL	0.1871 mL	0.3741 mL	0.9353 mL
	80 mM	0.0281 mL	0.1403 mL	0.2806 mL	0.7014 mL
	100 mM	0.0224 mL	0.1122 mL	0.2245 mL	0.5612 mL

BMS-986278 Related Classifications

Others

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BMS-9862782170126-74-4AdmilparantBMS986278BMS 986278LPL ReceptorLysophospholipid ReceptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

BMS-986278 (Synonyms: Admilparant)

Customer Review

BMS-986278 Related Antibodies

1 Publications Citing Use of MCE BMS-986278

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All LPL Receptor Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

BMS-986278 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

BMS-986278 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report